GB9221220D0
(en)
*
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
EP0710110B1
(de)
|
1993-04-23 |
2002-03-06 |
Abbott Laboratories |
Antikörper von rapamycinen mit offenem ring
|
US7279561B1
(en)
*
|
1993-04-23 |
2007-10-09 |
Wyeth |
Anti-rapamycin monoclonal antibodies
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
AU712193B2
(en)
|
1995-06-09 |
1999-10-28 |
Novartis Ag |
Rapamycin derivatives
|
GB9606452D0
(en)
*
|
1996-03-27 |
1996-06-05 |
Sandoz Ltd |
Organic compounds
|
US6984635B1
(en)
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
EP2298311B1
(de)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
US7063857B1
(en)
|
1999-04-30 |
2006-06-20 |
Sucampo Ag |
Use of macrolide compounds for the treatment of dry eye
|
US7067526B1
(en)
|
1999-08-24 |
2006-06-27 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
IL147803A0
(en)
|
1999-08-24 |
2002-08-14 |
Ariad Gene Therapeutics Inc |
28-epirapalogs
|
US6593292B1
(en)
|
1999-08-24 |
2003-07-15 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
US6790228B2
(en)
|
1999-12-23 |
2004-09-14 |
Advanced Cardiovascular Systems, Inc. |
Coating for implantable devices and a method of forming the same
|
US7807211B2
(en)
|
1999-09-03 |
2010-10-05 |
Advanced Cardiovascular Systems, Inc. |
Thermal treatment of an implantable medical device
|
US20070032853A1
(en)
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
US6776796B2
(en)
*
|
2000-05-12 |
2004-08-17 |
Cordis Corportation |
Antiinflammatory drug and delivery device
|
US8236048B2
(en)
|
2000-05-12 |
2012-08-07 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US7300662B2
(en)
*
|
2000-05-12 |
2007-11-27 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US20050002986A1
(en)
*
|
2000-05-12 |
2005-01-06 |
Robert Falotico |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
CA2424029C
(en)
|
2000-09-29 |
2008-01-29 |
Cordis Corporation |
Coated medical devices
|
US20040018228A1
(en)
*
|
2000-11-06 |
2004-01-29 |
Afmedica, Inc. |
Compositions and methods for reducing scar tissue formation
|
US20040241211A9
(en)
*
|
2000-11-06 |
2004-12-02 |
Fischell Robert E. |
Devices and methods for reducing scar tissue formation
|
US6534693B2
(en)
*
|
2000-11-06 |
2003-03-18 |
Afmedica, Inc. |
Surgically implanted devices having reduced scar tissue formation
|
BR0115715A
(pt)
|
2000-11-28 |
2004-02-03 |
Wyeth Corp |
Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2005201004A1
(en)
*
|
2001-02-19 |
2005-03-24 |
Novartis Ag |
Cancer treatment
|
AU2011226833B9
(en)
*
|
2001-02-19 |
2014-07-03 |
Novartis Ag |
Cancer treatment
|
PT2762140T
(pt)
|
2001-02-19 |
2017-07-04 |
Novartis Ag |
Resumo
|
AU2016206379B2
(en)
*
|
2001-02-19 |
2017-09-14 |
Novartis Ag |
Cancer Treatment
|
US6939376B2
(en)
*
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US7682387B2
(en)
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
AU2002366028A1
(en)
*
|
2001-11-21 |
2003-06-10 |
Sucampo Ag |
Use of fk506 and analogues for treating allergic diseases
|
WO2003068228A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
EP1542704A1
(de)
*
|
2002-04-18 |
2005-06-22 |
Stephen H. Embury |
VERFAHREN UND ZUSAMMENSETZUNG ZUR PRûVENTION VON SCHMERZEN BEI SICHELZELL-PATIENTEN
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
DE60324416D1
(de)
|
2002-05-16 |
2008-12-11 |
Novartis Ag |
Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
|
JP4265888B2
(ja)
*
|
2002-06-12 |
2009-05-20 |
株式会社リコー |
画像形成装置
|
EP1655372A3
(de)
|
2002-07-16 |
2008-01-16 |
Biotica Technology Limited |
Herstellung von Polyketiden und anderen natürlichen Produkten
|
RU2478378C2
(ru)
|
2002-09-24 |
2013-04-10 |
Новартис Аг |
Органические соединения
|
AU2003293529A1
(en)
|
2002-12-16 |
2004-07-29 |
Nitromed, Inc. |
Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
|
EP1594459B1
(de)
|
2002-12-30 |
2010-02-17 |
Angiotech International Ag |
Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
|
EP1636585B2
(de)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl-harnstoffe mit kinasehemmender wirkung
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
CN1882338A
(zh)
*
|
2003-09-18 |
2006-12-20 |
马库赛特公司 |
经巩膜递送
|
US7220755B2
(en)
*
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
US7780973B2
(en)
*
|
2003-12-15 |
2010-08-24 |
Ethicon Endo-Surgery, Inc. |
Method and device for minimally invasive implantation of biomaterial
|
US20050142161A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Freeman Lynetta J. |
Collagen matrix for soft tissue augmentation
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
GB0417852D0
(en)
|
2004-08-11 |
2004-09-15 |
Biotica Tech Ltd |
Production of polyketides and other natural products
|
US7901451B2
(en)
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US8021849B2
(en)
*
|
2004-11-05 |
2011-09-20 |
Siemens Healthcare Diagnostics Inc. |
Methods and kits for the determination of sirolimus in a sample
|
US20060258698A1
(en)
*
|
2005-02-09 |
2006-11-16 |
Sreenivasu Mudumba |
Liquid formulations for treatment of diseases or conditions
|
US8663639B2
(en)
*
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
US20100047338A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
GB0504544D0
(en)
|
2005-03-04 |
2005-04-13 |
Novartis Ag |
Organic compounds
|
GB0504994D0
(en)
*
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
EP1896018A2
(de)
|
2005-03-11 |
2008-03-12 |
Biotica Technology Limited |
Medizinische verwendungen von 39-desmethoxyrapamycin und seinen analogen
|
US20100061994A1
(en)
*
|
2005-03-11 |
2010-03-11 |
Rose Mary Sheridan |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
US7189582B2
(en)
*
|
2005-04-27 |
2007-03-13 |
Dade Behring Inc. |
Compositions and methods for detection of sirolimus
|
MX2008000897A
(es)
|
2005-07-20 |
2008-03-18 |
Novartis Ag |
Combinacion de una pirimidil-amino-benzamida y un inhibidor de cinasa mtor.
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
ES2611307T3
(es)
|
2005-08-30 |
2017-05-08 |
University Of Miami |
Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25)
|
US8492400B2
(en)
|
2006-02-09 |
2013-07-23 |
Santen Pharmaceutical Co., Ltd. |
Stable formulations, and methods of their preparation and use
|
JP5506378B2
(ja)
|
2006-03-23 |
2014-05-28 |
参天製薬株式会社 |
血管透過性に関連する疾患または病気のための製剤および方法
|
GB0609963D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
GB0609962D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
US7883855B2
(en)
|
2006-07-21 |
2011-02-08 |
Abbott Laboratories |
Immunosuppressant drug extraction reagent for immunoassays
|
US20080097591A1
(en)
*
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
US8067055B2
(en)
*
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
US20080103584A1
(en)
*
|
2006-10-25 |
2008-05-01 |
Biosensors International Group |
Temporal Intraluminal Stent, Methods of Making and Using
|
US8440185B2
(en)
|
2006-12-26 |
2013-05-14 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
WO2008083239A2
(en)
|
2006-12-27 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for stimulating an immune response
|
US7914999B2
(en)
|
2006-12-29 |
2011-03-29 |
Abbott Laboratories |
Non-denaturing lysis reagent
|
EP2118656B1
(de)
|
2006-12-29 |
2012-08-29 |
Abbott Laboratories |
Verbessertes testverfahren für immunsuppressiva
|
ES2405364T3
(es)
|
2006-12-29 |
2013-05-30 |
Abbott Laboratories |
Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
|
CA2673314C
(en)
|
2006-12-29 |
2014-03-11 |
Abbott Laboratories |
Non-denaturing lysis reagent for use with capture-in-solution immunoassay
|
US20080265343A1
(en)
*
|
2007-04-26 |
2008-10-30 |
International Business Machines Corporation |
Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
|
KR100930167B1
(ko)
*
|
2007-09-19 |
2009-12-07 |
삼성전기주식회사 |
초광각 광학계
|
CA2711765A1
(en)
|
2008-01-11 |
2009-07-16 |
Massachusetts Eye & Ear Infirmary |
Conditional-stop dimerizable caspase transgenic animals
|
DK2132228T3
(da)
|
2008-04-11 |
2011-10-10 |
Emergent Product Dev Seattle |
CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
|
EP2303250A1
(de)
|
2008-06-20 |
2011-04-06 |
Novartis AG |
Pädiatrische zusammensetzungen zur behandlung von multipler sklerose
|
CN104042612A
(zh)
|
2008-11-11 |
2014-09-17 |
得克萨斯大学体系董事会 |
哺乳动物雷帕霉素靶蛋白的抑制
|
CN102686600A
(zh)
|
2009-02-05 |
2012-09-19 |
托凯药业股份有限公司 |
甾体cyp17抑制剂/抗雄激素物质的新型药物前体
|
CN101924315B
(zh)
*
|
2009-06-16 |
2014-09-03 |
德昌电机(深圳)有限公司 |
换向器及其制造方法
|
EP2462165B1
(de)
|
2009-08-03 |
2016-05-11 |
University of Miami |
Verfahren zur in-vivo-expansion regulatorischer t-zellen
|
AU2010286361A1
(en)
|
2009-08-31 |
2012-03-15 |
Amplimmune, Inc. |
Methods and compositions for the inhibition of transplant rejection
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
CN102869358B
(zh)
|
2010-04-13 |
2016-03-23 |
诺华股份有限公司 |
用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合
|
BR112012026285A2
(pt)
|
2010-04-16 |
2016-07-12 |
Novartis Ag |
combinação de compostos orgânicos
|
EP2563391B1
(de)
|
2010-04-27 |
2020-08-26 |
Roche Glycart AG |
Kombinationstherapie eines afucosylierten CD20-Antikörpers mit einem mTOR-Inhibitor
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
CN103491955B
(zh)
|
2011-04-25 |
2015-12-23 |
诺华股份有限公司 |
磷脂酰肌醇-3-激酶(pi3k)抑制剂及mtor抑制剂的组合
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
EP2589383A1
(de)
|
2011-11-06 |
2013-05-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
FKBP-subtypspezifisches Rapamycin-Analogon zur Verwendung bei der Behandlung von Erkrankungen
|
RU2014124184A
(ru)
|
2011-11-15 |
2015-12-27 |
Новартис Аг |
Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5
|
GB201122305D0
(en)
|
2011-12-23 |
2012-02-01 |
Biotica Tech Ltd |
Novel compound
|
US9603800B2
(en)
|
2012-04-12 |
2017-03-28 |
Yale University |
Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
US20150290176A1
(en)
|
2012-10-12 |
2015-10-15 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
WO2014078522A1
(en)
|
2012-11-14 |
2014-05-22 |
Ohio State Innovation Foundation |
Materials and methods useful for treating glioblastoma
|
KR20150100716A
(ko)
|
2012-12-19 |
2015-09-02 |
앰플리뮨, 인크. |
항 인간 b7-h4 항체 및 이의 용도
|
CA2897826C
(en)
|
2013-01-09 |
2022-09-27 |
Taylor H. Schreiber |
Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
|
US20160030401A1
(en)
|
2013-03-13 |
2016-02-04 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
|
CA2904170A1
(en)
|
2013-03-14 |
2014-09-25 |
University Of Maryland, Baltimore |
Androgen receptor down-regulating agents and uses thereof
|
EP2997373A1
(de)
|
2013-05-17 |
2016-03-23 |
MedImmune, LLC |
Rezeptoren für b7-h4
|
WO2014200659A1
(en)
|
2013-06-11 |
2014-12-18 |
Clontech Laboratories, Inc. |
Protein enriched microvesicles and methods of making and using the same
|
CN105636594A
(zh)
|
2013-08-12 |
2016-06-01 |
托凯药业股份有限公司 |
使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
|
US9580758B2
(en)
|
2013-11-12 |
2017-02-28 |
Luc Montagnier |
System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
|
EA201690987A1
(ru)
|
2013-11-13 |
2016-10-31 |
Новартис Аг |
Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
AU2014373683B2
(en)
|
2013-12-31 |
2020-05-07 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
BR112016014903A8
(pt)
|
2014-02-11 |
2018-05-02 |
Novartis Ag |
combinações farmacêuticas que compreendem um inibidor de pi3k, seu uso, sua preparação combinada, e embalagem comercial
|
EP3811970A1
(de)
|
2014-03-15 |
2021-04-28 |
Novartis AG |
Regulierbarer chimärer antigenrezeptor
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
US10300070B2
(en)
|
2014-03-27 |
2019-05-28 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
CA2940671A1
(en)
|
2014-04-07 |
2015-10-15 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
EP3131546B1
(de)
|
2014-04-16 |
2022-02-16 |
Rapamycin Holdings, Inc. |
Orale rapamycinformulierung zur verwendung bei der behandlung von feliner chronischer gingivo-stomatitis (fcgs)
|
US10258639B2
(en)
|
2014-05-06 |
2019-04-16 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
|
WO2015187541A1
(en)
|
2014-06-02 |
2015-12-10 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
EP3193915A1
(de)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Kombinationen aus niedrigen, immunfördernden dosen von mtor-inhibitoren und cars
|
EP4205749A1
(de)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimierte chimäre antigenrezeptorhaltige zellen
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
DK3183268T3
(da)
|
2014-08-19 |
2020-05-11 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
|
CN107073066B
(zh)
|
2014-09-11 |
2021-09-17 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
CN114621969A
(zh)
|
2014-09-17 |
2022-06-14 |
诺华股份有限公司 |
用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
|
SG11201702895SA
(en)
|
2014-10-08 |
2017-05-30 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
CN107106588B
(zh)
|
2014-10-28 |
2020-08-11 |
山口晃史 |
用于改善妊娠状态的药剂及其使用
|
WO2016066608A1
(en)
|
2014-10-28 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
|
FR3033499A1
(fr)
|
2015-03-11 |
2016-09-16 |
Centre Leon-Berard |
Composition pour le traitement des tumeurs neuroendocrines pancreatiques
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
CN106188093B
(zh)
*
|
2015-05-08 |
2018-06-12 |
上海医药工业研究院 |
一种雷帕霉素结构类似物及其制备方法
|
US10576076B2
(en)
|
2015-05-20 |
2020-03-03 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
CN108351687B
(zh)
|
2015-09-04 |
2022-01-07 |
耶鲁大学 |
靶向胰腺和结肠的聚合胆汁酸纳米组合物
|
KR20180080230A
(ko)
|
2015-11-11 |
2018-07-11 |
노파르티스 아게 |
미오스타틴 길항제의 용도, 이들을 함유하는 조합물 및 그의 용도
|
US20190117799A1
(en)
|
2016-04-01 |
2019-04-25 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
US20190290593A1
(en)
|
2016-04-29 |
2019-09-26 |
Icahn School Of Medicine At Mount Sinai |
Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
|
CN109641947B
(zh)
|
2016-07-20 |
2023-04-14 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
JP7069177B2
(ja)
|
2016-09-21 |
2022-05-17 |
ネクストキュア インコーポレイテッド |
シグレック-15に対する抗体及びその使用方法
|
US10525083B2
(en)
|
2016-10-07 |
2020-01-07 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
|
KR20190089005A
(ko)
|
2016-11-23 |
2019-07-29 |
노파르티스 아게 |
에베롤리무스, 닥톨리십 또는 둘 다를 사용하여 면역 반응을 증진시키는 방법
|
US20200081010A1
(en)
|
2016-12-02 |
2020-03-12 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
UA124474C2
(uk)
|
2016-12-22 |
2021-09-22 |
Емджен Інк. |
БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
|
SG11201908226XA
(en)
|
2017-02-10 |
2019-10-30 |
Mount Tam Therapeutics Inc |
Rapamycin analog
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
US20210154372A1
(en)
|
2017-05-15 |
2021-05-27 |
C.R. Bard, Inc. |
Medical device with drug-eluting coating and intermediate layer
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3679040B1
(de)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitoren von kras g12c und verfahren zur verwendung davon
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
IL278335B1
(en)
|
2018-05-01 |
2024-05-01 |
Revolution Medicines Inc |
C26-linked rapamycin analogs as MTOR inhibitors
|
ES2945560T3
(es)
|
2018-05-01 |
2023-07-04 |
Revolution Medicines Inc |
Análogos de rapamicina unidos en C40, C28 y C-32 como inhibidores de mTOR
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3788038B1
(de)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
CA3103661A1
(en)
|
2018-05-09 |
2019-11-14 |
Yale University |
Particles for spatiotemporal release of agents
|
WO2019217661A1
(en)
|
2018-05-09 |
2019-11-14 |
Yale University |
Compositions and systems for ex vivo cell modulation and methods of use thereof
|
AU2019265822B2
(en)
|
2018-05-10 |
2024-07-18 |
Amgen Inc. |
KRAS G12C inhibitors for the treatment of cancer
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
JP7369719B2
(ja)
|
2018-06-12 |
2023-10-26 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
SG11202012447YA
(en)
*
|
2018-06-15 |
2021-01-28 |
Navitor Pharm Inc |
Rapamycin analogs and uses thereof
|
CN112533599A
(zh)
|
2018-08-10 |
2021-03-19 |
山口晃史 |
与母体和胎儿的关系中的体液免疫相关的疾病的治疗药
|
JP7262581B2
(ja)
|
2018-11-14 |
2023-04-21 |
ルトニックス,インコーポレーテッド |
改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
MX2021005700A
(es)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Inhibidores de kras g12c y metodos de uso de los mismos.
|
AU2019401108A1
(en)
|
2018-12-18 |
2021-07-01 |
Koushi Yamaguchi |
Agent for improving infertility, recurrent miscarriage, and state of pregnancy
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
MA54543A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
EP3898592A1
(de)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Als kif18a-inhibitoren verwendbare heteroarylamide
|
EP3914245A4
(de)
|
2019-01-22 |
2022-08-24 |
Aeovian Pharmaceuticals, Inc. |
Mtorc-1-modulatoren und verwendungen davon
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
CN113727758A
(zh)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
双环杂环基化合物及其用途
|
WO2020209828A1
(en)
|
2019-04-08 |
2020-10-15 |
Bard Peripheral Vascular, Inc. |
Medical device with drug-eluting coating on modified device surface
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
CA3140392A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
WO2021001743A1
(en)
|
2019-07-02 |
2021-01-07 |
Effector Therapeutics, Inc. |
Translation inhibitors and uses thereof
|
MX2022001181A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
CA3147276A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220402916A1
(en)
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
AU2020372881A1
(en)
|
2019-10-28 |
2022-06-09 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of KRAS G12C mutant
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
CR20220240A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
MX2022005360A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
BR112022008858A2
(pt)
|
2019-11-08 |
2022-09-06 |
Revolution Medicines Inc |
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の改善された合成
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
TW202134234A
(zh)
*
|
2019-12-05 |
2021-09-16 |
美商奈維特製藥公司 |
雷帕黴素類似物及其用途
|
KR20220124768A
(ko)
|
2020-01-07 |
2022-09-14 |
레볼루션 메디슨즈, 인크. |
Shp2 억제제 투여 및 암 치료방법
|
KR20230084095A
(ko)
|
2020-03-27 |
2023-06-12 |
에오비안 파마슈티컬스, 인크. |
Mtorc1 조절제 및 이의 용도
|
US20230174518A1
(en)
|
2020-04-24 |
2023-06-08 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
CN116600789A
(zh)
|
2020-06-19 |
2023-08-15 |
耶鲁大学 |
用于诱导耐受性的聚合胆汁酸酯纳米颗粒
|
WO2022014640A1
(ja)
|
2020-07-15 |
2022-01-20 |
大鵬薬品工業株式会社 |
腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
|
EP4185590A2
(de)
*
|
2020-07-21 |
2023-05-31 |
Aeovian Pharmaceuticals, Inc. |
Mtorc1-modulatoren und verwendungen davon
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
JP2023541916A
(ja)
|
2020-09-15 |
2023-10-04 |
レボリューション メディシンズ インコーポレイテッド |
がんの治療における、ras阻害剤としてのインドール誘導体
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
JP2024511067A
(ja)
|
2021-03-19 |
2024-03-12 |
トレインド セラピューティクス ディスカバリー,インコーポレーテッド |
訓練された免疫を調節するための化合物およびその使用方法
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
EP4334321A1
(de)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras-inhibitoren
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
CN117769554A
(zh)
|
2021-05-28 |
2024-03-26 |
大鹏药品工业株式会社 |
Kras突变蛋白的小分子抑制剂
|
CA3223081A1
(en)
|
2021-07-15 |
2023-01-19 |
Samir Mitragotri |
Compositions and methods relating to cells with adhered particles
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|